{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:30:42Z","timestamp":1773214242864,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T00:00:00Z","timestamp":1223424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Use of a central venous access device (CVAD) can facilitate early introduction of home\u2010based infusion of factor concentrate for long\u2010term prophylaxis or immune tolerance therapy in children with bleeding disorders. The aim was <jats:bold>t<\/jats:bold>o review outcomes associated with use of CVAD. Retrospective review of paediatric patients with bleeding disorders was observed at the Mayo Clinic Comprehensive Hemophilia Center. Thirty\u2010seven CVAD were placed in 18 patients (haemophilia A [<jats:italic>n<\/jats:italic>\u2003=\u200315], type 3 von Willebrand disease [<jats:italic>n\u2003<\/jats:italic>=\u20032] and haemophilia B [<jats:italic>n<\/jats:italic>\u2003=\u20031]). Follow\u2010up was for 45\u2003952 CVAD days, and median time that CVAD remained in place was 1361\u2003days per device. Factor VIII (FVIII) inhibitors were present in 4 of the 15 patients. Ten CVAD\u2010related infections occurred (median, 672\u2003days; range, 72\u20131941\u2003days), of which six were in one patient with FVIII inhibitors. Overall infection rate was 0.22 (95% confidence interval [CI], 0.10\u20130.40) per 1000 CVAD days, with 0.11 infections in patients without FVIII inhibitors compared with a pooled incidence of 0.66 (95% CI, 0.44\u20130.97) reported in the literature. Indications for removal of 27 CVAD were blockage, change to peripheral venous access, catheter displacement, infection, leak in the port septum, short catheter and skin erosion. No clinically apparent thrombosis or sequelae of thrombosis were observed. Infection is the most common complication associated with CVAD use and is increased in patients who have inhibitors. The low rate of clinically apparent thrombosis reflects our practice of not screening for thrombosis. The low infection rate reflects our practice of using and reinforcing the aseptic technique.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2008.01906.x","type":"journal-article","created":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T19:28:07Z","timestamp":1223494087000},"page":"168-174","source":"Crossref","is-referenced-by-count":25,"title":["Central venous access devices for paediatric patients with haemophilia: a single\u2010institution experience"],"prefix":"10.1111","volume":"15","author":[{"given":"R.","family":"TITAPIWATANAKUN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"MOIR","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. K.","family":"PRUTHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. L.","family":"STAVLO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. A.","family":"SCHMIDT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"RODRIGUEZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,15]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440418.x"},{"key":"e_1_2_8_3_2","volume-title":"MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding)","author":"Medical and Scientific Advisory Council (MASAC) document #179","year":"2007"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00556.x"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/088800100276569"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.1985.tb02329.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(99)00124-5"},{"key":"e_1_2_8_8_2","volume-title":"surveillance definitions: central line associated bloodstream infection (CLABSI) and related sites","author":"National Healthcare Safety Network (NHSN)","year":"2006"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197412262912604"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e318068b1d6"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00943.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(03)00043-2"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00557.x"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(98)70386-5"},{"key":"e_1_2_8_16_2","first-page":"189","article-title":"Use of implantable venous access devices in children with severe hemophilia: benefits and burden","volume":"89","author":"Van Dijk K","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05270.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00381.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00909.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3643178.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.9.s1.7.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00840.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1998.tb01412.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00793.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199707000-00013"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00692.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2008.01906.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2008.01906.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T10:11:01Z","timestamp":1697364661000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2008.01906.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1365-2516.2008.01906.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01906.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}